Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Abstract

Complete remissions of a variety of B-cell malignancies lasting ≥ 3 years occurred after 51% of evaluable anti-CD19 CAR T-cell treatments. Remissions of up to 9 years are ongoing. Late adverse events were rare.